基本信息
浏览量:338
职业迁徙
个人简介
Con is passionate about developing new treatment for blood cancers. He is the global lead for the BTK inhibitor zanubrutinib, and oversaw its development from the first human dosed (in Melbourne) to successful international licensing studies worldwide. Con designed and performed the first global study to combine ibrutinib and venetoclax, publishing the results in the New England Journal of Medicine 5 years after inception. In 2015, he became the Australian lead for the pivotal study of Tisagenlecleucel in diffuse large B-cell lymphoma, leading to public funding for CAR T-cells as standard treatment in Australia.
研究兴趣
论文共 656 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Blood Advances (2024)
Meng-Xiao Luo,Tania Tan,Marie Trussart, Annika Poch, Thi Minh Hanh Nguyen,Terence P. Speed,Damien G. Hicks, Esther Bandala-Sanchez,Hongke Peng,Stéphane Chappaz, Charlotte Slade,Daniel T Utzschneider,
biorxiv(2024)
Blood advancesno. 7 (2024): 1639-1650
Javid J. Moslehi,Richard R. Furman,Constantine S. Tam, Joe-Elie Salem,Christopher R. Flowers,Aileen Cohen, Meng Zhang, Jun Zhang, Lipeng Chen, Han Ma,Jennifer R. Brown
Blood advances (2024)
Md Ashik Ullah,Beatriz Garcillan,Eden Whitlock,William A. Figgett,Simona Infantino,Mahya Eslami, SiLing Yang, M. Arifur Rahman, Yong H. Sheng,Nicholas Weber,Pascal Schneider,Constantine S. Tam,
Frontiers in immunology (2024)
Masa Lasica,Mary A Anderson, Alex Boussioutas,Gareth P Gregory,Nada Hamad,Kate Manos,Penny McKelvie, Michael Ng,Belinda Campbell,Emma Palfreyman,Ross Salvaris,Robert Weinkove,
Internal medicine journalno. 6 (2024): 1017-1030
Bloodno. 8 (2024): 673-684
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn